-
In the first half of the year, drug registration applications increased in general, and there was no domestic approval for 19 varieties of generic applications
Time of Update: 2017-07-12
Abstract in June, the application for registration of new drugs continued to pick up, and in the first half of the year, the overall trend was on the rise In June, three new drugs of category 1 entere
-
There are three advantages for the use of rare disease drugs. Will generic drugs for orphan drugs break the ice first?
Time of Update: 2017-07-10
Rare diseases refer to the diseases with low prevalence and rarity There are different definitions of rare diseases in the world The World Health Organization defines rare diseases as diseases or path
-
Inventory of Roche's key products listed in China
Time of Update: 2017-07-05
When it comes to Roche, the first thing we think about is Roche's blood glucose meter?! Yes, Roche from Basel, Switzerland is not only the world leader in pharmaceutical business, but also the world l
-
2017h1 domestic drug registration and application trend: Class 1 new drug blowout, East Sunshine explosion
Time of Update: 2017-07-03
In the first half of 2017 (as of June 30), CDE has undertaken 2119 drug registration applications (calculated by acceptance number, the same below), down 139 from the first half of 2016 (2258) In term
-
The company raised 1.286 billion yuan to go through IPO again, and Chenxin pharmaceutical went public with ups and downs
Time of Update: 2017-07-02
Recently, Chen Xin Pharmaceutical disclosed the prospectus on the website of the CSRC The company plans to issue no more than 100 million shares on the Shanghai Stock Exchange, with a total share capi
-
Who is the driving force behind the turnover trend in the pharmaceutical industry?
Time of Update: 2017-06-29
In two years, more than 15 managers above the director level of an enterprise have been replaced, and the old people of the older enterprise have also been replaced In the past two years, personnel ch
-
In the first half of this year, who will be the winner of opening up the international market?
Time of Update: 2017-06-27
In the increasingly competitive international market, pharmaceutical companies from China are no longer rare On the basis of NDA, anda becomes an important reference factor to judge the international
-
Generic drugs have been approved one after another + medical insurance, stirring the hepatitis B market for novofibrate
Time of Update: 2017-06-27
With the acceleration of the listing process of tenofovir generic drugs, Chengdu Beite tenofovir dipivoxil tablets (2016.11.23), Fujian guangshengtang pharmaceutical's tenofovir dipivoxil capsules (20
-
The first domestic new anticancer drug, furaquinotinib, is on the market. The market of tinib is changing soon!
Time of Update: 2017-06-26
Recently, the first phase 3 clinical study of fqtinib, developed independently by Hutchison Whampoa, has reached the end point and been put on the market for approval, which means that another heavy a
-
Lost 1.1 billion! 1.1 new drugs can turn this pharmaceutical company around?
Time of Update: 2017-06-23
Recently, tailing pharmaceutical announced that the new indication "myelodysplastic syndrome (MDS)" of the company's national 1.1 new drug, xiticol (uropolypeptide injection), was included in the "maj
-
High density alarm! Three trends of clinical trials in pharmaceutical enterprises
Time of Update: 2017-06-22
As the cost of clinical projects rises again and again, enterprises choose to start clinical projects more and more cautiously Therefore, by analyzing which projects start clinical and which projects
-
Revenue 120.8 billion yuan! 26 over 100 million varieties! An article to see through the innovative chess game of Shangyao
Time of Update: 2017-06-20
In the environment of great change, we should actively seek change, take innovation and internationalization as the future development strategy, and actively push forward and break through the courage
-
The market of newly approved antineoplastic drugs is surging
Time of Update: 2017-06-15
With the acceleration of drug review and approval, a number of major imported new drugs have been launched this year Among them, the main imported tumor products are: pezopanil tablets of Glaxo, afati
-
How far is it from the market value of 100 billion yuan after "one dismantling and three dismantling"?
Time of Update: 2017-06-14
On June 13, Yaoming biotechnology was successfully listed on the stock exchange of Hong Kong with an opening price of HK $25.00 and a closing price of HK $27.950 as of the morning According to Yao's a
-
Three "wolves" of domestic generic drugs are coming!
Time of Update: 2017-06-12
First, a large number of original research has been turned into real estate; second, generic drugs have been put on the market in Europe, the United States and Japan; third, a large number of overseas
-
Sinopharm group: Six listed companies speed up the adjustment when the reform is in progress
Time of Update: 2017-06-11
As the only Chinese pharmaceutical enterprise that has entered the list of the world's top 500 for four consecutive years, the China Pharmaceutical Group directly managed by the state owned assets sup
-
Exclusive interpretation: over duplication of drugs in "severely affected areas"
Time of Update: 2017-06-08
In order to open the information, guide the registration and application policies of pharmaceutical enterprises, and reduce the waste of resources, CFDA issued the list of over repeated drugs for two
-
Fosun's merger and acquisition will begin! Split medical equipment company to Hong Kong for financing
Time of Update: 2017-06-08
With the approval of Hong Kong stock exchange for Fosun Pharmaceutical's split of sisram, it means that its strategy to build a financing platform for medical devices has officially spread, followed b
-
Analysis report on CDE drug review in May 2017
Time of Update: 2017-06-08
Highlights: in May, there were 378 new acceptance numbers undertaken by CDE (excluding 13 reviews, counting by acceptance numbers, the same below) In this month, CDE accepted 36 acceptance numbers of
-
Hengrui 4 class 1 new drugs apply for clinical 10 exclusive varieties to apply for CDE
Time of Update: 2017-06-07
Abstract in May, the application for new drug registration picked up Hengrui pharmaceutical had 4 new drugs of class 1 applied for clinical application 10 of the generic drug applications are currentl
